Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity
- 254 Downloads
Radioembolization of liver metastases of neuroendocrine neoplasms (NEN) has shown promising results; however, the current literature is of limited quality. A large international, multicentre retrospective study was designed to address several shortcomings of the current literature.
244 NEN patients with different NEN grades were included.
Primary outcome parameters were radiologic response 3 and 6 months after treatment according to RECIST 1.1 and mRECIST. Secondary outcome parameters included clinical response, clinical and biochemical toxicities.
Radioembolization resulted in CR in 2%, PR in 14%, SD in 75% and PD 9% according to RECIST 1.1 and in CR in 8%, PR in 35%, SD in 48% and PD in 9% according to mRECIST. Objective response rates improved over time in 20% and 26% according to RECIST 1.1. and mRECIST, respectively. Most common new grade 3–4 biochemical toxicity was lymphocytopenia (6.7%). No unexpected clinical toxicities occurred. Radioembolization-specific complications occurred in < 4%. In symptomatic patients, improvement and resolution of symptoms occurred in 44% and 34%, respectively. Median overall survival from first radioembolization was 3.7, 2.7 and 0.7 years for G1, G2 and G3, respectively. Objective response is independent of NEN grade or primary tumour origin. Significant prognostic factors for survival were NEN grade/Ki67 index, ≥ 75% intrahepatic tumour load, the presence of extrahepatic disease and disease control rate according to RECIST 1.1.
Safety and efficacy of radioembolization in NEN patients was confirmed with a high disease control rate of 91% in progressive patients and alleviation of NEN-related symptoms in 79% of symptomatic patients.
Level of evidence
KeywordsRadioembolization SIRT NEN NET Neuroendocrine tumor
Travel expenses and accommodations of AJATB were partially covered by Sirtex Medical Europe, producer of SIR-spheres. Remaining travel expenses were granted by the Girard de Mielet van Coehoorn Foundation (Grant of the Board of Directors UMC Utrecht, the Netherlands). Both parties have no access to the data and have not been involved in data analysis or in the writing of the manuscript.
Compliance with Ethical Standards
Conflict of interest
C.M.D. has acted as a consultant for Sirtex, Bayer Healthcare and Ipsen. A.F. receives research funding from Ipsen, Novartis and Sirtex Medical. D.B.B is a consultant for BTG, receives research funding from Sirtex and has served on a speaker’s bureau for Boston Scientific. D.Y.S. has acted as consultant for BTG, Boston Scientific, Amgen, EmbolX and Viralytics. M.G.E.H.L. has acted as a consultant for BTG, Sirtex, Mirada and Bayer Healthcare. All other authors have no conflicts of interest to declare.
- 3.Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76. https://doi.org/10.1159/000335597.CrossRefGoogle Scholar
- 7.Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–77. https://doi.org/10.1016/S0140-6736(15)00817-X.CrossRefGoogle Scholar
- 15.Response Evaluation Criteria In Solid Tumors. www.recist.com. Accessed March 2016.
- 17.USA NCI. Common terminology criteria in adverse events, version 4.03 (CTCAE v4.03). NIH. 2010. http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf. Accessed March 2016.
- 18.Ludwig JM, Ambinder EM, Ghodadra 3, et al. Lung shunt fraction prior to yttrium-90 radioembolization predicts survival in patients with neuroendocrine liver metastases: single-center prospective analysis. Cardiovasc Intervent Radiol. 2016;39(7):1007–14. https://doi.org/10.1007/s00270-016-1323-4.
- 28.Tomozawa Y, Jahangiri Y, Pathak P, Kolbeck KJ, Schenning RC, Kaufman JA, Farsad K. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol. 2018;29(6):858–65. https://doi.org/10.1016/j.jvir.2018.02.002.CrossRefGoogle Scholar
- 30.Elschot M, Nijsen JF, Lam MGEH, et al. (99m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 166Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41(10):1965–75. https://doi.org/10.1007/s00259-014-2784-9.CrossRefGoogle Scholar
- 32.Braat AJAT, Kwekkeboom DJ, Kam BLR, et al. Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol. 2018;18(1):84. https://doi.org/10.1186/s12876-018-0817-8.CrossRefGoogle Scholar
- 33.Mikell JK, Mahvash A, Siman W, et al. Selective internal radiation therapy with yttrium-90 glass microspheres: biases and uncertainties in absorbed dose calculations between clinical dosimetry models. Int J Radiat Oncol Biol Phys. 2016;96(4):888–96. https://doi.org/10.1016/j.ijrobp.2016.07.021.CrossRefGoogle Scholar
- 34.Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–68. https://doi.org/10.1007/s00259-013-2395-x.CrossRefGoogle Scholar
- 36.Chansanti O, Jahangiri Y, Matsui Y, et al. tumor dose response in yttrium-90 resin microsphere embolization for neuroendocrine liver metastases: a tumor-specific analysis with dose estimation using SPECT-CT. J Vasc Interv Radiol. 2017;28(11):1528–35. https://doi.org/10.1016/j.jvir.2017.07.008.CrossRefGoogle Scholar
- 37.Fidelman N, Kerlan RK Jr, Hawkins RA, et al. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014;45(2):168–80. https://doi.org/10.1007/s12029-013-9566-7.CrossRefGoogle Scholar
- 38.Turkmen C, Ucar A, Poyanli A, et al. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease. Cancer Biother Radiopharm. 2013;28(7):534–40. https://doi.org/10.1089/cbr.2012.1455.CrossRefGoogle Scholar